Dimensional Fund Advisors LP Acquires 102,646 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Dimensional Fund Advisors LP raised its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 52.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 297,106 shares of the biotechnology company's stock after buying an additional 102,646 shares during the period. Dimensional Fund Advisors LP owned about 1.39% of Enanta Pharmaceuticals worth $1,708,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ENTA. JPMorgan Chase & Co. grew its holdings in shares of Enanta Pharmaceuticals by 53.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company's stock valued at $2,524,000 after purchasing an additional 85,082 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Enanta Pharmaceuticals by 9.3% during the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock valued at $5,348,000 after purchasing an additional 79,197 shares during the last quarter. Trexquant Investment LP boosted its position in Enanta Pharmaceuticals by 97.3% during the 4th quarter. Trexquant Investment LP now owns 135,954 shares of the biotechnology company's stock valued at $782,000 after buying an additional 67,040 shares during the period. Assenagon Asset Management S.A. boosted its position in Enanta Pharmaceuticals by 34.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company's stock valued at $1,109,000 after buying an additional 49,050 shares during the period. Finally, Thrivent Financial for Lutherans purchased a new stake in Enanta Pharmaceuticals during the 4th quarter valued at $254,000. Institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:ENTA traded up $0.07 on Tuesday, hitting $6.03. The company had a trading volume of 17,884 shares, compared to its average volume of 284,581. The firm's 50-day simple moving average is $5.47 and its two-hundred day simple moving average is $6.55. Enanta Pharmaceuticals, Inc. has a 1 year low of $4.09 and a 1 year high of $17.24. The firm has a market capitalization of $128.80 million, a price-to-earnings ratio of -1.21 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million during the quarter, compared to the consensus estimate of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. Equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on ENTA shares. JMP Securities reissued a "market outperform" rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th. Finally, HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $17.25.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.